{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T06:58:31Z","timestamp":1769151511394,"version":"3.49.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.clindermatol.2020.05.003","type":"journal-article","created":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T16:14:39Z","timestamp":1589472879000},"page":"775-780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Evidence-based best practice advice for patients treated with systemic immunosuppressants in relation to COVID-19"],"prefix":"10.1016","volume":"38","author":[{"given":"Fabrizio","family":"Galimberti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"McBride","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Cronin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Abrouk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Kirsner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2020.05.003_bb0005","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0010","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0015","series-title":"Dermatology: ExpertConsult","year":"2012"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0020","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jid.2016.08.034","article-title":"Infections in moderate to severe psoriasis patients treated with biological drugs compared to classic systemic drugs: findings from the BIOBADADERM registry","volume":"137","author":"D\u00e1vila-Seijo","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0025","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/j.1468-3083.2011.04230.x","article-title":"Risk of Herpes zoster in patients with psoriasis treated with biologic drugs","volume":"26","author":"Dreiher","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0030","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/00007890-198610000-00009","article-title":"Impairment of the immune response to influenza vaccination in renal transplant recipients by cyclosporine, but not azathioprine","volume":"42","author":"Versluis","year":"1986","journal-title":"Transplantation"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0035","doi-asserted-by":"crossref","unstructured":"Narayanan L, Mulligan C, Durso L, et al: Recovery of T-cell function in healthy dogs following cessation of oral cyclosporine administration [e-pub ahead of print] (PMID: 31914237). Vet Med Sci, https:\/\/doi.org\/10.1002\/vms3.230. accessed XXX.","DOI":"10.1002\/vms3.230"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0040","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1007\/s007050050629","article-title":"Comparison of the effect of FK506 and cyclosporin A on virus production in H9 cells chronically and newly infected by HIV-1","volume":"144","author":"Briggs","year":"1999","journal-title":"Arch Virol"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0045","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.virol.2011.01.011","article-title":"Involvement of cyclophilin B in the replication of Japanese encephalitis virus","volume":"412","author":"Kambara","year":"2011","journal-title":"Virology"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0050","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1053\/j.gastro.2006.08.027","article-title":"Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha","volume":"131","author":"Henry","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0055","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.antiviral.2018.05.007","article-title":"Effect of interferon alpha and cyclosporine treatment separately and in combination on Middle East Respiratory Syndrome Coronavirus (MERS-CoV) replication in a human in-vitro and ex-vivo culture model","volume":"155","author":"Li","year":"2018","journal-title":"Antivir Res"},{"issue":"Pt 8","key":"10.1016\/j.clindermatol.2020.05.003_bb0060","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1099\/vir.0.052910-0","article-title":"MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-\u03b1 treatment","volume":"94","author":"de Wilde","year":"2013","journal-title":"J Gen Virol"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002331","article-title":"The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors","volume":"7","author":"Pfefferle","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0070","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.3390\/v5051250","article-title":"Suppression of coronavirus replication by cyclophilin inhibitors","volume":"5","author":"Tanaka","year":"2013","journal-title":"Viruses"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0075","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.virusres.2014.02.010","article-title":"Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir","volume":"184","author":"Carbajo-Lozoya","year":"2014","journal-title":"Virus Res"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0080","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.virusres.2012.02.002","article-title":"Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506","volume":"165","author":"Carbajo-Lozoya","year":"2012","journal-title":"Virus Res"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0085","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2165\/00003495-199651020-00007","article-title":"Mycophenolate mofetil: a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation","volume":"51","author":"Fulton","year":"1996","journal-title":"Drugs"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0090","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.det.2004.09.006","article-title":"The use of systemic immune moderators in dermatology: an update","volume":"23","author":"Kazlow Stern","year":"2005","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0095","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/MOT.0b013e3283592622","article-title":"Influenza vaccination in solid-organ transplant recipients","volume":"17","author":"Cordero","year":"2012","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0100","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02149-19","article-title":"Identification and characterization of novel compounds with broad-spectrum antiviral activity against influenza A and B viruses","volume":"94","author":"Park","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.antiviral.2014.12.011","article-title":"Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus","volume":"115","author":"Cheng","year":"2015","journal-title":"Antivir Res"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0110","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.rdc.2015.08.004","article-title":"Infection risk and safety of corticosteroid use","volume":"42","author":"Youssef","year":"2016","journal-title":"Rheum Dis Clin N Am"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0115","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/jlb.60.5.563","article-title":"Regulation of cytokine and cytokine receptor expression by glucocorticoids","volume":"60","author":"Almawi","year":"1996","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0120","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood.V79.1.45.45","article-title":"Glucocorticoids downregulate gene expression of GM-CSF, NAP-1\/IL-8, and IL-6, but not of M-CSF in human fibroblasts","volume":"79","author":"Tobler","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0125","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/clinids\/11.6.954","article-title":"Risk of infectious complications in patients taking glucocorticosteroids","volume":"11","author":"Stuck","year":"1989","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0130","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/1203475418811335","article-title":"Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies","volume":"23","author":"Papp","year":"2019","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0135","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-019-4669-9","article-title":"Severe acute respiratory infection risk following glucocorticosteroid treatment in uncomplicated influenza-like illness resulting from pH1N1 influenza infection: a case control study","volume":"19","author":"Xing","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0140","first-page":"2437","article-title":"Management of Herpes zoster (shingles) and postherpetic neuralgia","volume":"61","author":"Stankus","year":"2000","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0145","first-page":"2893","article-title":"Short-term efficacy and safety of prednisone in herpes zoster and the effects on IL-6 and IL-10","volume":"18","author":"Peng","year":"2019","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0150","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.23812\/CONTI-E","article-title":"Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies","volume":"34","author":"Conti","year":"2020","journal-title":"J Biol Regul Homeost Agents"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0160","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","article-title":"Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury","volume":"395","author":"Russell","year":"2020","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0165","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0140-6736(20)30361-5","article-title":"On the use of corticosteroids for 2019-nCoV pneumonia","volume":"395","author":"Shang","year":"2020","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0170","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1365-2613.2008.00575.x","article-title":"The haemotoxicity of azathioprine in repeat dose studies in the female CD-1 mouse","volume":"89","author":"Molyneux","year":"2008","journal-title":"Int J Exp Pathol"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0175","doi-asserted-by":"crossref","first-page":"E17","DOI":"10.1111\/j.1399-0012.2009.01095.x","article-title":"Influenza virus vaccination in kidney transplant recipients: serum antibody response to different immunosuppressive drugs","volume":"24","author":"Salles","year":"2010","journal-title":"Clin Transpl"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0180","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1177\/0961203313493032","article-title":"Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies","volume":"22","author":"Danza","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0185","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/tid.12095","article-title":"Safety profile comparing azathioprine and mycophenolate in kidney transplant recipients receiving tacrolimus and corticosteroids","volume":"15","author":"Cristelli","year":"2013","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0190","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/QAD.0000000000000121","article-title":"Azathioprine can be safely used in HIV-infected individuals","volume":"28","author":"Chamberlain","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0195","doi-asserted-by":"crossref","first-page":"R109","DOI":"10.1186\/ar2764","article-title":"Predictors of major infections in systemic lupus erythematosus","volume":"11","author":"Ruiz-Irastorza","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0200","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000082102","article-title":"The biology of CD20 and its potential as a target for mAb therapy","volume":"8","author":"Cragg","year":"2005","journal-title":"Curr Dir Autoimmun"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0205","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1002\/art.38107","article-title":"Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response","volume":"65","author":"M\u00e9let","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0210","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1681\/ASN.2015050523","article-title":"B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome","volume":"27","author":"Colucci","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0215","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1001\/jamadermatol.2019.1121","article-title":"Risk of serious infection in patients receiving systemic medications for the treatment of psoriasis","volume":"155","author":"Dommasch","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0220","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1136\/annrheumdis-2018-213222","article-title":"Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial","volume":"77","author":"Park","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0225","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-014032","article-title":"Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case\u2013control study in Asia","volume":"7","author":"Liao","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0230","first-page":"375","article-title":"Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis","volume":"22","author":"Hagiyama","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0235","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3390\/v11040338","article-title":"Mechanism of action of methotrexate against zika virus","volume":"11","author":"Beck","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0240","doi-asserted-by":"crossref","first-page":"9411","DOI":"10.1128\/JVI.00101-13","article-title":"Flaviviruses are sensitive to inhibition of thymidine synthesis pathways","volume":"87","author":"Fischer","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0245","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: the promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0250","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1089\/1079990041535610","article-title":"Potent inhibition of SARS-associated coronavirus (SCOV) infection and replication by type I interferons (IFN-alpha\/beta) but not by type II interferon (IFN-gamma)","volume":"24","author":"Zheng","year":"2004","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0255","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nm1001","article-title":"Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques","volume":"10","author":"Haagmans","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000849","article-title":"SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism","volume":"6","author":"Frieman","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000240","article-title":"MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV","volume":"4","author":"Sheahan","year":"2008","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0270","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(03)13973-6","article-title":"Treatment of SARS with human interferons","volume":"362","author":"Cinatl","year":"2003","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0275","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","article-title":"Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated rheumatoid arthritis patients","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0280","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/annrheumdis-2014-207191","article-title":"The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0285","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaad.2020.03.031","article-title":"Should biologics for psoriasis be interrupted in the era of COVID-19?","volume":"82","author":"Lebwohl","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0290","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/jdv.14163","article-title":"Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis","volume":"31","author":"Blauvelt","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0295","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/j.1365-2133.2009.09238.x","article-title":"Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept","volume":"161","author":"Ortonne","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2020.05.003_bb0300","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2133.2012.10941.x","article-title":"Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab\u2019 certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension","volume":"167","author":"Reich","year":"2012","journal-title":"Br J Dermatol"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X20300912?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X20300912?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:18:57Z","timestamp":1760033937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X20300912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0738081X20300912"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2020.05.003","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence-based best practice advice for patients treated with systemic immunosuppressants in relation to COVID-19","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2020.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}